Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases

被引:88
作者
Osswald, Matthias [1 ,2 ]
Blaes, Jonas [1 ,2 ]
Liao, Yunxiang [1 ,2 ]
Solecki, Gergely [1 ,2 ]
Goemmel, Miriam [1 ,2 ]
Berghoff, Anna S. [1 ,2 ]
Salphati, Laurent [3 ]
Wallin, Jeffrey J. [4 ]
Phillips, Heidi S. [4 ]
Wick, Wolfgang [1 ,2 ]
Winkler, Frank [1 ,2 ]
机构
[1] Univ Heidelberg Hosp, Neurol Clin & Natl Ctr Tumor Dis, Neuenheimer Feld 400, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Clin Cooperat Unit Neurooncol, German Canc Consortium DKTK, Heidelberg, Germany
[3] Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA
[4] Genentech Inc, Dept Canc Signaling & Translat Oncol, San Francisco, CA 94080 USA
关键词
PI3K PATHWAY; CANCER; PERMEABILITY; MELANOMA; EFFICACY; CHEMOTHERAPY; MULTICENTER; RESISTANCE; REVEALS; BIOLOGY;
D O I
10.1158/1078-0432.CCR-16-1327
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The role of blood-brain barrier (BBB) integrity for brain tumor biology and therapy is a matter of debate. Experimental Design: We developed a new experimental approach using in vivo two-photon imaging of mouse brain metastases originating from a melanoma cell line to investigate the growth kinetics of individual tumor cells in response to systemic delivery of two PI3K/mTOR inhibitors over time, and to study the impact of microregional vascular permeability. The two drugs are closely related but differ regarding a minor chemical modification that greatly increases brain penetration of one drug. Results: Both inhibitors demonstrated a comparable inhibition of downstream targets and melanoma growth in vitro. In vivo, increased BBB permeability to sodium fluorescein was associated with accelerated growth of individual brain metastases. Melanoma metastases with permeable microvessels responded similarly to equivalent doses of both inhibitors. In contrast, metastases with an intact BBB showed an exclusive response to the brain-penetrating inhibitor. The latter was true for macro-and micrometastases, and even single dormant melanoma cells. Nuclear morphology changes and single-cell regression patterns implied that both inhibitors, if extravasated, target not only perivascular melanoma cells but also those distant to blood vessels. Conclusions: Our study provides the first direct evidence that nonpermeable brain micro-and macrometastases can effectively be targeted by a drug designed to cross the BBB. Small-molecule inhibitors with these optimized properties are promising agents in preventing or treating brain metastases in patients. (C)2016 AACR.
引用
收藏
页码:6078 / 6087
页数:10
相关论文
共 50 条
  • [1] Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model
    On, Ngoc H.
    Mitchell, Ryan
    Savant, Sanjot D.
    Bachmeier, Corbin. J.
    Hatch, Grant M.
    Miller, Donald W.
    JOURNAL OF NEURO-ONCOLOGY, 2013, 111 (02) : 133 - 143
  • [2] PSMA-targeted nanoparticles for specific penetration of blood-brain tumor barrier and combined therapy of brain metastases
    Ni, Jiang
    Miao, Tongtong
    Su, Ma
    Khan, Naveed Ullah
    Ju, Xiufeng
    Chen, Haiyan
    Liu, Feng
    Han, Liang
    JOURNAL OF CONTROLLED RELEASE, 2021, 329 : 934 - 947
  • [3] Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption
    Blanchette, Marie
    Tremblay, Luc
    Lepage, Martin
    Fortin, David
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2014, 34 (05) : 820 - 826
  • [4] Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases
    Bernatz, Simon
    Ilina, Elena I.
    Devraj, Kavi
    Harter, Patrick N.
    Mueller, Klaus
    Kleber, Sascha
    Braun, Yannick
    Penski, Cornelia
    Renner, Christoph
    Halder, Rashi
    Jennewein, Lukas
    Solbach, Christine
    Thorsen, Frits
    Pestalozzi, Bernhard C.
    Mischo, Axel
    Mittelbronn, Michel
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (01)
  • [5] Nanoparticles Surmounting Blood-Brain Tumor Barrier Through Both Transcellular and Paracellular Pathways to Target Brain Metastases
    Miao, Tongtong
    Ju, Xiufeng
    Zhu, Qiuning
    Wang, Yamei
    Guo, Qian
    Sun, Tao
    Lu, Chunzhu
    Han, Liang
    ADVANCED FUNCTIONAL MATERIALS, 2019, 29 (27)
  • [6] Role of the Blood-Brain Barrier in the Formation of Brain Metastases
    Wilhelm, Imola
    Molnar, Judit
    Fazakas, Csilla
    Hasko, Janos
    Krizbai, Istvan A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (01): : 1383 - 1411
  • [7] The Acute Impact of Propofol on Blood-Brain Barrier Integrity in Mice
    Nozohouri, Ehsan
    Ahn, Yeseul
    Zoubi, Sumaih
    Patel, Dhavalkumar
    Archie, Sabrina Rahman
    Akter, Khondker Ayesha
    Siddique, Muhammad Bilal
    Huang, Juyang
    Abbruscato, Thomas J.
    Bickel, Ulrich
    PHARMACEUTICAL RESEARCH, 2024, 41 (08) : 1599 - 1611
  • [8] The effect of thermal therapy on the blood-brain barrier and blood-tumor barrier
    Patel, Bhuvic
    Yang, Peter H.
    Kim, Albert H.
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2020, 37 (02) : 35 - 43
  • [9] Sortilin regulates blood-brain barrier integrity
    Toth, Andrea E.
    Helms, Hans C.
    Harazin, Andras
    Johnsen, Kasper B.
    Goldeman, Charlotte
    Burkhart, Annette
    Thomsen, Maj S.
    Kempen, Paul J.
    Klepe, Adrian
    Lipka, Dora V.
    Moller, Peter L.
    Andresen, Thomas L.
    Nyegaard, Mette
    Moos, Torben
    Brodin, Birger
    Nielsen, Morten S.
    FEBS JOURNAL, 2022, 289 (04) : 1062 - 1079
  • [10] Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood-Brain Barrier
    Aasen, Synnove Nymark
    Espedal, Heidi
    Holte, Christopher Florian
    Keunen, Olivier
    Karlsen, Tine Veronika
    Tenstad, Olav
    Maherally, Zaynah
    Miletic, Hrvoje
    Tuyen Hoang
    Eikeland, Anne Vaag
    Baghirov, Habib
    Olberg, Dag Erlend
    Pilkington, Geoffrey John
    Sarkar, Gobinda
    Jenkins, Robert B.
    Sundstrom, Terje
    Bjerkvig, Rolf
    Thorsen, Frits
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (11) : 2171 - 2181